---
title: "The innovative drug concept has repeatedly strengthened, and JLPC has achieved 6 limit-ups in 8 days"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248704338.md"
description: "The concept of innovative drugs has repeatedly strengthened, with popular stock JLPC achieving 6 limit-ups in 8 days, InventisBio rising over 5% to set a new historical high, and Li Sheng Pharmaceutical, Guangsheng Tang, Asia-Pacific Pharmaceutical, Livzon Pharmaceutical, and Anglikang all rising over 5%"
datetime: "2025-07-16T02:22:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248704338.md)
  - [en](https://longbridge.com/en/news/248704338.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248704338.md)
generator: "portal-rs"
---

# The innovative drug concept has repeatedly strengthened, and JLPC has achieved 6 limit-ups in 8 days

The concept of innovative drugs has repeatedly strengthened, with popular stock JLPC achieving 6 limit-ups in 8 days, InventisBio rising over 5% to set a new historical high, and Li Sheng Pharmaceutical, Guangsheng Tang, Asia-Pacific Pharmaceutical, Livzon Pharmaceutical, and Anglikang all rising over 5%

### Related Stocks

- [600513.CN](https://longbridge.com/en/quote/600513.CN.md)
- [688382.CN](https://longbridge.com/en/quote/688382.CN.md)

## Related News & Research

- [Subscribe for Symbiotec Pharmalab Ltd IPO; Ajcon Global](https://longbridge.com/en/news/296742246.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [08:36 ETUltimate Men's HQ Launches Private Product-Match Education Experience](https://longbridge.com/en/news/296789283.md)
- [Germany's AfD eyes Saxony-Anhalt win as first step toward federal power](https://longbridge.com/en/news/296707147.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**